Bacillus subtilis pb2441 partially attenuates hepatic steatosis with transcriptomic changes broadly similar to dapagliflozin in a Western diet mouse model
Yangrae Cho, Min-Kyu Kim, Kyoung-Sik Moon · 2026
Read Bacillus subtilis pb2441 partially attenuates hepatic steatosis with transcriptomic changes broadly similar to dapagliflozin in a Western diet mouse model by Yangrae Cho, Min-Kyu Kim, Kyoung-Sik Moon (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13478210.txt.
Description
Cho and colleagues fed mice a Western diet in 2026 to model fatty liver disease, then tested whether a probiotic bacterium could soften the damage. The strain, Bacillus subtilis pb2441, was compared against dapagliflozin, a diabetes drug known to help fatty livers. Western feeding fattens the liver, inflames it, and scars it, and the team read the liver's gene activity to see how each treatment answered.
Both treatments partly reversed the liver fat seen under the microscope, and both lowered liver triglycerides, the stored fat measured chemically, though only the drug group's drop reached significance. Gene patterns moved the same way in both groups, with fat-building genes turned down and fat-burning genes restored toward normal in the treated mice. The probiotic's effects ran consistently weaker than the drug's, so the authors present it as a partial, drug-like influence worth further study.
Catalog record
| CREATOR | Yangrae Cho, Min-Kyu Kim, Kyoung-Sik Moon |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |